DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04200625

Completed

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity

Assets

Dulaglutide / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

80

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥27

Primary endpoint

•Epicardial Fat thickness

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04200625
Org study ID20190944

Timeline

Milestones

Study start2019-09-24actual
Primary completion2019-12-09actual
Study completion2019-12-09actual
Study first posted2019-12-16actual
Last update posted2023-05-10actual

Assets

Investigational agents

DulaglutideSemaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age90 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Type 2 diabetic subjects who routinely come to the University of Miami Division of Diabetes, Endocrinology and Metabolism outpatient diabetic clinic, as standard of care.

Inclusion criteria

•Type 2 diabetes,
•BMI ≥27 kg/m2,
•Age ≥ 18 years old

Exclusion criteria

•Type 1 diabetes
•Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors
•History of diabetic ketoacidosis
•Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2
•Acute infective diseases, cancer or chemotherapy
•Use of systemic corticosteroids within the 3 months prior this study
•Known or suspected allergy to semaglutide or dulaglutide excipients or related products
•Pregnancy, breastfeeding or the intention of becoming pregnant

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

Epicardial Fat thickness

Time frame:12 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.